Properties
What is it?
International Nonproprietary Name - methilprednisolon Clinical-pharmacological group: Glucocorticoids → Glucocorticoid agents for injection Composition Lyophilisate: Active substance – methylprednisolone (in the form of methylprednisolone sodium succinate) 40 mg, 125 mg, 250 mg, 500 mg, 1000 mg. Excipients: Sodium dihydrogen phosphate monohydrate, sodium phosphate. Solvent: Benzyl alcohol 9 mg, water for injection up to 1 ml. Description of the medicinal form - Lyophilisate for preparation of intravenous and intramuscular injection solution Lyophilisate 40 mg, 125 mg, 250 mg: Lyophilized powder or porous white or almost white mass. Solvent – clear colorless solution. - Lyophilisate for preparation of intravenous and intramuscular injection solution Lyophilisate 500 mg, 1000 mg: Lyophilized powder or porous white or almost white mass. Solvent – clear colorless solution with a faint odor of benzyl alcohol. Indications Administered only by doctor's prescription to prevent complications 1. Endocrine diseases - Primary and secondary adrenocortical insufficiency (if necessary, with mineralocorticoids, especially in pediatric practice). - Acute adrenocortical insufficiency (necessity of adding mineralocorticoids may arise). - Shock due to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenocortical insufficiency is suspected (when mineralocorticoid action is undesirable). - Preoperative period for severe trauma and severe diseases, in patients with suspected or established adrenocortical insufficiency. - Congenital adrenal hyperplasia. - Subacute thyroiditis. - Hypercalcemia associated with oncological diseases. 2. Rheumatic diseases (short-term, as adjunctive therapy to overcome the acute period or during exacerbations) - Post-traumatic osteoarthritis. - Synovitis in osteoarthritis. - Rheumatoid arthritis, including juvenile rheumatoid arthritis (in some cases, maintenance therapy with low doses may be required). - Acute and subacute bursitis. - Epicondylitis. - Acute non-specific tenosynovitis. - Acute gouty arthritis. - Psoriatic arthritis. - Ankylosing spondylitis. 3. Systemic connective tissue diseases (during exacerbations or in some cases, as maintenance therapy) - Systemic lupus erythematosus (and lupus nephritis). - Acute rheumatic carditis. - Systemic dermatomyositis (polymyositis). - Nodular periarteritis. - Goodpasture's syndrome. 4. Skin diseases - Pemphigus. - Severe erythema multiforme (Stevens-Johnson syndrome). - Exfoliative dermatitis. - Severe psoriasis. - Dermatitis herpetiformis bullosa. - Severe seborrheic dermatitis. - Mycosis fungoides. 5. Allergic conditions (in severe or individual conditions when conventional therapy is ineffective) - Bronchial asthma. - Contact dermatitis. - Atopic dermatitis. - Serum sickness. - Seasonal or perennial allergic rhinitis. - Drug hypersensitivity. - Post-transfusion purpura. - Acute non-infectious laryngeal edema. Dosage and administration Solu-Medrol® can be administered by IV or IM injection or IV infusion, but in emergencies, treatment is primarily initiated with intravenous injection. Lower doses are administered to children (but not less than 0.5 mg/kg/day), however, dose selection primarily considers the severity of the condition and the patient's response to therapy, not weight and age. As adjunctive therapy in life-threatening conditions, 30 mg/kg body weight intravenously over 30 minutes. This dose can be repeated every 4-6 hours for no more than 48 hours.